Candid Therapeutics raised $370M in a Series A funding round to develop antibody drugs for inflammatory diseases.
Candid Therapeutics raised $370M in a Series A funding round to develop antibody drugs for inflammatory diseases.
09/09/24, 1:34 PM
Location
Money raised
$370 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Candid Therapeutics, a new biotech company, secured over $370 million in funding to develop treatments for autoimmune diseases. The funding will allow them to operate for several years and explore opportunities for an initial public offering.